Topical glaucoma medications: Possible implications on the meibomian glands
Research output: Contribution to journal › Review › Research › peer-review
Standard
Topical glaucoma medications : Possible implications on the meibomian glands. / Fineide, Fredrik; Magnø, Morten; Dahlø, Kristian; Kolko, Miriam; Heegaard, Steffen; Vehof, Jelle; Utheim, Tor Paaske.
In: Acta Ophthalmologica, 2024.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Topical glaucoma medications
T2 - Possible implications on the meibomian glands
AU - Fineide, Fredrik
AU - Magnø, Morten
AU - Dahlø, Kristian
AU - Kolko, Miriam
AU - Heegaard, Steffen
AU - Vehof, Jelle
AU - Utheim, Tor Paaske
N1 - Publisher Copyright: © 2024 The Author(s). Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
PY - 2024
Y1 - 2024
N2 - One of the most common causes of blindness on a global scale is glaucoma. There is a strong association between glaucoma and increased intraocular pressure (IOP). Because of this, adequate IOP-lowering is the most important treatment strategy, mostly through topical eyedrops. Well-functioning meibomian glands are paramount for maintaining a stable tear film, and their dysfunction is the most common cause of dry eye disease. There is a growing concern that both topical glaucoma medications themselves and their added preservatives damage the meibomian glands, and consequently, the ocular surface. Preserved topical glaucoma medications appear to cause dysfunction and atrophy of the meibomian glands. Upon comparison, preserved formulations caused more symptoms of dry eye, tear film instability, inflammatory changes and meibomian gland dropout than the preservative-free counterpart. However, although seemingly less detrimental, unpreserved alternatives may diminish glandular efficacy, and, depending on the active ingredient, lead to glandular death. This negatively impacts quality of life, adherence to treatment regimens and prognosis. In this review, we explore the available evidence regarding the effects of IOP-lowering eye drops on the meibomian glands.
AB - One of the most common causes of blindness on a global scale is glaucoma. There is a strong association between glaucoma and increased intraocular pressure (IOP). Because of this, adequate IOP-lowering is the most important treatment strategy, mostly through topical eyedrops. Well-functioning meibomian glands are paramount for maintaining a stable tear film, and their dysfunction is the most common cause of dry eye disease. There is a growing concern that both topical glaucoma medications themselves and their added preservatives damage the meibomian glands, and consequently, the ocular surface. Preserved topical glaucoma medications appear to cause dysfunction and atrophy of the meibomian glands. Upon comparison, preserved formulations caused more symptoms of dry eye, tear film instability, inflammatory changes and meibomian gland dropout than the preservative-free counterpart. However, although seemingly less detrimental, unpreserved alternatives may diminish glandular efficacy, and, depending on the active ingredient, lead to glandular death. This negatively impacts quality of life, adherence to treatment regimens and prognosis. In this review, we explore the available evidence regarding the effects of IOP-lowering eye drops on the meibomian glands.
KW - dry eye disease
KW - glaucoma
KW - meibography
KW - meibomian gland dysfunction
KW - ocular surface
KW - topical medications
U2 - 10.1111/aos.16728
DO - 10.1111/aos.16728
M3 - Review
C2 - 38822682
AN - SCOPUS:85194823322
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
SN - 1755-375X
ER -
ID: 395081339